Dr. Labiento Smith controls early myopia progression with low-dose Atropine and/or Orthokeratology. She bases her treatment on the current literature and recent LAMP study. These treatments for myopia control are considered an off-label use in the United States.. The medication Atropine and Ortho-K are FDA approved but under a different category and use. All children with active myopia progression at Sudbury Eye Care are seen bi-annually for exams to monitor progression.
Dr. Labiento and her staff are supportive, professional, kind, and experts. I have been a patient for many years. I deeply respect Dr. Labiento as she has cared for me and identified eye issues early on. She treated me quickly without complications. They have worked with my busy schedule to fit me in. I recommend Dr. Labiento for your eye care. They also have a great selection of glasses!
Susan M. — Google